Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Poria Cocos Polysaccharides Target NRF2-Ferroptosis
2026-09-11
The reference study identifies a mechanistic connection between Poria cocos polysaccharides, NRF2 regulation, and ferroptosis in alcoholic liver disease. Using rat and alcohol-injured cell models, it shows that PCP improves biochemical and inflammatory injury markers while reducing oxidative and iron-associated damage, providing a framework for studying NRF2-dependent hepatoprotection.
-
Plant Autophagy: Condensates-to-VAPVs Pathway
2026-09-11
Jiang et al. identify a plant-specific condensates-to-VAPVs conversion pathway that directs autophagosomes toward vacuolar degradation. The study links VPS41 organization, ARLA1 GTPases, SNARE coupling, autophagic flux, and plant survival, while showing that Arabidopsis autophagy is largely independent of the canonical RAB7 route.
-
Patient-Derived Gastric Cancer Assembloids
2026-09-10
This 2025 study introduces patient-matched gastric cancer assembloids that combine tumor organoids with tumor-derived stromal subpopulations. The model captures stromal effects on gene expression and drug response, creating a more physiologically relevant platform for studying resistance and personalized treatment strategies.
-
Erlotinib (NSC 718781): EGFR Research Guide
2026-09-10
Erlotinib (NSC 718781) is an orally bioavailable, reversible EGFR tyrosine kinase inhibitor with nanomolar biochemical and cellular potency. This guide connects EGFR pathway inhibition with reproducible assay design and clarifies why emerging SCUBE3 biology does not yet establish an erlotinib-specific mechanism.
-
A40926: From Biosynthesis to Assay Design
2026-09-09
A40926 is a dalbavancin precursor whose biosynthetic regulation directly informs reproducible antibacterial research. This guide connects engineered fermentation, mechanism-based assay design, MIC interpretation, and translational limitations in one evidence-grounded framework.
-
Halazone: From Water Disinfection to Ion-Channel Insight
2026-09-09
Halazone is more than a conventional water disinfection agent: its HOCl-generating chemistry supports rapid bactericidal workflows, while comparative nerve-fiber experiments reveal how oxidative modification can reshape sodium-current inactivation. This article connects those domains without overstating the evidence, offering translational researchers a practical framework for assay design, product selection, and future antimicrobial resistance research.
-
Perospirone Assay Design: Receptor to Kv1.5
2026-09-08
Perospirone and SM-9018 free base provide a powerful paired model for studying receptor pharmacology alongside vascular ion-channel effects. This article presents an evidence-led assay strategy that connects schizophrenia research with carefully bounded cardiovascular investigation.
-
IPR-803 and uPAR–uPA Inhibition in Metastasis
2026-09-08
The reference study established compound 4, identified here as IPR-803, as a chemically tractable inhibitor of the urokinase receptor–urokinase-type plasminogen activator interaction. By combining synthesis, orthogonal binding assays, invasion studies, pharmacokinetics, and a breast cancer metastasis model, the authors connected direct uPAR engagement with reduced tumor-cell invasion and lung metastatic burden.
-
Deep Learning and iPSC-CMs for Cardiotoxicity
2026-09-07
Grafton et al. developed a high-content screening workflow that combines human iPSC-derived cardiomyocytes with deep-learning image analysis to identify cardiotoxic phenotypes early in discovery. The study shows how a compact, phenotype-based score can prioritize compounds with diverse mechanisms while also highlighting important limits on translating cellular signals into clinical cardiac risk.
-
MOB1A/B Loss Rewires Intestinal Signaling
2026-09-07
Bae et al. show that intestinal epithelial MOB1A/B depletion produces an unusual combination of early epithelial hyperproliferation, Wnt suppression, stem-cell loss, and BMP/TGF-β activation. Pharmacological pathway inhibition partially restores secretory-cell differentiation but not intestinal stem-cell pools, positioning MOB1A/B as an important coordinator of epithelial homeostasis.
-
Phosbind Acrylamide for Protein Phosphorylation
2026-09-05
Phosbind Acrylamide enables antibody-independent separation of phosphorylated and non-phosphorylated proteins during SDS-PAGE. This workflow connects practical phosphorylation-state analysis with the CLK4–NEXN mechanism implicated in pathological cardiac hypertrophy.
-
HAX1, SARS-CoV-2 Spike, and the Unfolded Protein Response
2026-09-04
The 2025 FEBS Journal study identifies HAX1 as a host-cell binding partner and regulator of SARS-CoV-2 spike-induced unfolded protein response signaling. Its findings distinguish spike-specific ER stress from generic stress induction and connect HAX1 loss with increased reactive oxygen species and mitochondrial dysfunction.
-
Tropifexor (LJN452): FXR Research Guide
2026-09-04
Tropifexor, also called LJN452, is a potent synthetic Farnesoid X Receptor agonist for mechanistic FXR signaling and intestinal epithelial barrier function research. Its reported EC50 is approximately 0.2 nM, but potency does not by itself establish tissue selectivity, therapeutic efficacy, or clinical utility.
-
3D Tumor Spheroids for Glioblastoma Stemness
2026-09-03
The reference study presents a streamlined 96-well 3D tumor spheroid assay for functionally assessing stem-like behavior in human glioblastoma and glioma cell lines. By reducing dependence on prolonged, multiround sphere-forming workflows, the method supports faster comparisons of experimental interventions while retaining the need for orthogonal stemness validation.
-
Elobixibat hydrate: IBAT Inhibition for GI Research
2026-09-03
Elobixibat hydrate is a selective ileal bile acid transporter inhibitor that increases intestinal bile acid exposure and supports research on constipation, bowel preparation, and metabolic signaling. The C8720 product has low systemic exposure, high protein binding, and formulation-specific solvent guidance documented by the product information.